UK Markets close in 7 hrs 42 mins

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
642.60-6.20 (-0.96%)
As of 4:59PM CEST. Market open.
Full screen
Previous close648.80
Open651.00
Bid0.00 x 0
Ask642.60 x 0
Day's range637.60 - 653.60
52-week range406.90 - 684.50
Volume1,424,001
Avg. volume1,894,077
Market cap1.476T
Beta (5Y monthly)0.27
PE ratio (TTM)34.93
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.35 (1.45%)
Ex-dividend date16 Aug 2021
1y target estN/A
All
News
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period

  • Globe Newswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

    Bagsværd, Denmark, 11 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their a

  • Globe Newswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021

    Bagsværd, Denmark, 10 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their a